Clinical trials: Pustular; Psoriasis, Palmaris Et Plantaris
Psoriasis Vulgaris, Psoriatic Arthritis
A Phase 4 Clinical Study of Brodalumab
This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003…
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Pustular; Psoriasis, Palmaris Et Plantaris, Psoriatic Erythroderma
- Trial name
- NCT04183881
- Testing
- Brodalumab 210mg SC
- Where
- Japan
- Volunteers
- 138 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Palmoplantar Pustulosis
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT04061252
- Testing
- KHK4827
- Where
- 2 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Palmoplantar Pustulosis
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.
- Trial name
- NCT05710185
- Testing
- Deucravacitinib
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Brigham and Women's Hospital
Palmoplantar Pustulosis
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT03988335
- Testing
- RIST4721
- Where
- 17 sites in Canada, Germany
- Volunteers
- 35 people
- Sponsor
- Aristea Therapeutics, Inc.
Palmoplantar Pustulosis
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.
- Trial name
- NCT05194839
- Testing
- RIST4721
- Where
- 51 sites in United States, Canada and 5 more
- Volunteers
- 79 people
- Sponsor
- Aristea Therapeutics, Inc.
Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab.
- Trial name
- NCT04493424
- Testing
- Spesolimab
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP)
Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists
This study aims to determine if an artificial intelligence (AI) medical device can help healthcare professionals more accurately diagnose rare and complex skin conditions.
- Conditions
- Pustular Psoriasis (PP), Generalized Pustular Psoriasis (GPP), Eczema Atopic Dermatitis, Acute Generalized Exanthematous Pustulosis
- Trial name
- LegitHealth BI (NCT07428915)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- AI Labs Group S.L
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
- Trial name
- POPLAR (NCT03633396)
- Testing
- Imsidolimab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Vanda Pharmaceuticals
Palmoplantar Pustulosis, Generalized Pustular Psoriasis
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
This study plans to calculate the prevalence and incidence of palmoplantar pustulosis and generalized pustular psoriasis based on the national medical insurance data and analyze the composition characteristics and some clinical…
- Trial name
- NCT04566471
- Testing
- prevalence/incidence
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Palmoplantar Pustulosis
Picankibart in Palmoplantar Pustulosis
1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to…
- Trial name
- NCT07552454
- Testing
- Picankibart
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
- Trial name
- BeSeen (NCT07219420)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Canada and 11 more
- Volunteers
- 320 people
- Sponsor
- UCB Biopharma SRL
Palmoplantar Pustulosis
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis…
- Trial name
- NCT07013201
- Testing
- Delgocitinib cream, Vehicle cream
- Where
- 40 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- LEO Pharma
Psoriasis (PsO), Psoriatic Arthritis
Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information
Psoriasis is a globally prevalent chronic relapsing skin disease, characterized by its long duration and tendency to relapse. In addition to skin symptoms, it can also affect nails and joints, leading to pathological features…
- Conditions
- Psoriasis (PsO), Psoriatic Arthritis, Palmoplantar Pustulosis (PPP), Plaque Psoriasis
- Trial name
- NCT06790940
- Testing
- No intervention
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Palmoplantar Pustulosis (PPP)
Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a rare, chronic inflammatory skin disease primarily affecting the palms and soles. Currently, no treatment is specifically approved for PPP globally.
- Trial name
- NCT07530367
- Testing
- Tofacitinib, Imatinib
- Where
- China
- Volunteers
- 135 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Palmoplantar Pustulosis
Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis
The goal of this clinical trial is to investigate the efficacy and safety of Deucravacitinib in patients with moderate-to-severe palmoplantar pustulosis.
- Trial name
- NCT07000630
- Testing
- Deucravacitinib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking University First Hospital
Palmoplantaris Pustulosis
A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
The purpose of this study is to assess the efficacy, safety, and tolerability of CNTO 1959 following subcutaneous administration in participants with palmoplantar pustulosis.
- Trial name
- NCT01845987
- Testing
- CNTO 1959
- Where
- 8 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis (PPP)
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles.
- Trial name
- NCT04451720
- Testing
- Risankizumab
- Where
- 39 sites in Japan
- Volunteers
- 119 people
- Sponsor
- AbbVie
Psoriasis
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
- Trial name
- NCT03135548
- Testing
- Spesolimab (low dose), Spesolimab (high dose)
- Where
- 18 sites in Canada, Denmark and 4 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.
- Trial name
- NCT02641730
- Testing
- Guselkumab
- Where
- 32 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis
A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in Japan
The purpose of this study is to describe the treatment patterns of participants receiving systemic treatment for of palmoplantar pustulosis (PPP) in Japan.
- Trial name
- ProPuP (NCT04459507)
- Testing
- No intervention
- Where
- 39 sites in Japan
- Volunteers
- 276 people
- Sponsor
- Janssen Pharmaceutical K.K.